跳到主要內容區塊

研究人員｜中央研究院 細胞與個體生物學研究所

研究人員
:::
側邊選單開關 研究人員
:::

文章內容區

  • 吳漢忠Han-Chung Wu
    特聘研究員Distinguished Research Fellow
    • 專長：Cancer Research, Cell Biology
    • 信箱：hcw0928@gate.sinica.edu.tw
    • 電話：02-2789-9528
    • 網站： 吳漢忠老師實驗室
    • 位置：R411/ICOB
友善列印
經歷簡介展開收合
2020-
Distinguished Research Fellow, Institute of Cellular and Organismic Biology, Academia Sinica
2019-
Director, National Biotechnology Research Park/Biomedical Translation Research Center (BioTReC), Academia Sinica
2019-
Chief Executive Officer (CEO), National Biotechnology Research Park/BioHub Taiwan
2016- 2018
Director, Department of Intellectual Property and Technology Transfer, Academia Sinica
2010-
Professor,Institute of Pathology, National Taiwan University
2010-2020
Research Fellow, Institute of Cellular and Organismic Biology, Academia Sinica
2017- 2018
Acting Director, Institute of Cellular and Organismic Biology, Academia Sinica
2010-2016
Vice Director in Institute of Cellular and Organismic Biology, Academia Sinica
1993
Ph.D. Institute of Pathology, National Taiwan University, Taiwan
研究方向展開收合

吳漢忠博士為中研院細胞與個體生物學研究所特聘研究員兼國家生技研究園區生醫轉譯研究中心主任及台灣大學醫學院教授。他致力於癌症及傳染病兩大研究領域，著重在基礎及轉譯醫學研究。吳博士的研究興趣在於尋找新的腫瘤抗原及開發新穎藥物傳輸系統應用於腫瘤的分子影像與治療。他發展出一套噬菌體顯現法(Phage display)來尋找特殊表現受體，用於產生全人抗體，並鑑定多種腫瘤標靶胜肽。研究至今共計發表超過125篇論文於知名國際期刊及申請117項專利，其中80項已獲得專利。目前有68項專利包含了20項技術已成功授權給生技公司，7項技術授權正在進行臨床試驗或已成為市場銷售的產品，另外有7項專利正在進行前臨床研究。研究成果不僅在基礎研究和應用科學領域具有重要價值，也為生物技術產業和藥物開發的發展做出了具體的貢獻，於2020年12月獲選為「美國國家發明家學院（National Academy of Inventors, NAI）」院士，此為學術發明家的最高榮耀。自 2019年底新冠肺炎疫情爆發以來，本實驗室積極開發治療和檢測 SARS-CoV-2 的單株抗體，已成功研發檢測新冠病毒抗原快篩組及檢測新冠病毒抗體快篩組，兩者皆已獲得TFDA專案製造許可。另外，也已成功開發COVID-19之治療性抗體。

代表著作展開收合
  1. Lin, C. Y., Wang, Y. L., Chi, Y. H., Chan, L. Y., Ho, C. T., Chen, G. W., Hsu, H. C., Hwang, D. W., Wu, H. C.* and Hung, S. C.* (2022). Functionalized osteoarthritis targeting peptides for MRI, lubricant and regenerative medicine. Nature Biomedical Engineering. (Accepted)
  2. Li, H. J., Ke, F. Y., Lin, C.C., Lu, M. Y., Kuo, Y. H., Wang, Y. P., Lin, S. C., Chang, Y. H., Chen, H. Y., Yang, P. C. and Wu, H. C.* (2021). ENO1 promotes lung cancer metastasis via HGFR and WNT signaling-driven epithelial-mesenchymal transition. Cancer Research 81, 4094-4109. 
  3. Chen, H. N., Liang, K. H., Lai, J. K., Lan, C. H., Liao, M. Y. Hung, S. H., Chuang, Y. T. and Wu, H. C.* (2020). EpCAM signaling promotes tumor progression and protein stability of PD-L1 through EGFR pathway. Cancer Research 80, 5035-5050.
  4. Liang, K. H., Tso, H. C., Hung, S. H., Kuan, I. I., Lai, J. K., Ke, F. Y., Chuang, Y. T., Liu, I. J., Wang, Y. P., Chen, R. H. and Wu, H. C.* (2018). Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells. Cancer Letters 433, 165-175.    
  5. Chi, Y. H., Hsiao, J. K., Lin, M. H., Chang, C, Lan, C. H. and Wu, H. C.* (2017). Lung cancer-targeting peptides with multi-subtype indication for combinatorial drug delivery and molecular imaging. Theranostics 7, 1612-1632.  
  6. Yeh, C. Y., Hsiao, J. K., Wang, Y. P., Lan, C. H. and Wu, H. C.* (2016). Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer. Biomaterials 99, 1-15.
  7. Wu, C. H., Kuo, Y. H., Hong, R. L., Wu, H. C.* (2015). α-Enolase-binding peptide enhances drug delivery efficiency and therapeutic efficacy against colorectal cancer. Science Translational Medicine 7, 290ra91, 1-14. 
  8. Wang, Y. P., Liu, I. J., Chiang, C. P. and Wu, H. C.* (2013) Astrocyte elevated gene-1 is associated with metastasis in head and neck squamous cell carcinoma through p65 phosphorylation and upregulation of MMP1. Molecular Cancer 12, 109.
  9. Lu, R. M., Chang, Y. L., Chen, M. S. and Wu, H. C.* (2011). Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor targeted imaging and drug delivery. Biomaterials 32, 3265-3274.
  10. Lee, T. Y., Lin, C. T., Kuo, S. Y., Chang D. K. and Wu, H. C.* (2007). Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Research 67, 10958-10965.